Clinical Trial Update: A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS) [Phase 3]

View source ↗

Summary

A Phase 3 multicenter study evaluating NB-001 for recurrent herpes labialis (SHaRCS) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Labialis

Drugs mentioned

• NB-001

Snippet

Sponsor: NanoBio Corporation | Conditions: Recurrent Herpes Labialis | Phase 3 | Status: COMPLETED